The global anti-migraine drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The market growth is mainly attributed to the rising cases of migraine across the globe coupled with growing clinical trials for anti-migraine drugs. According to the Migraine Research Foundation, migraine is the 3rd largest prevalent disease across the globe. In 2018, more than 1 billion people were suffering from migraine. As per the same source, migraine is most prevalent between the age of 18 and 44 and mostly occurred in women more than men. Further, in 2018, there were around 39 million cases of migraine in the US alone. This further provides a boost to the global anti-migraine drugs market.

Some key players operating in the market include Eli Lilly & Co., Abbott Laboratories, and Allergan plc, among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. Further, pipeline clinical trials by various pharmaceutical companies such as Amgen Inc., and Allergen plc, among others further provide ample opportunity to the market growth. For instance, in March 2019 Axsome Therapeutics, Inc. started the phase III clinical trial for drugs AXS-07, Meloxicam, Rizatriptan, and Placebo for the treatment of acute migraine. AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. Such activities are further projected to offer substantial growth opportunities to the global anti-migraine drugs market during the forecast period.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Eli Lilly & Co., Abbott Laboratories, and Allergan plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Anti-Migraine Drugs Market Report by Segment

By Type

• Triptans
• Ergots
• Others

By Application

• Men
• Women

Global Anti-Migraine Drugs Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa